News Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:25:00 10/04/2026 pm IST			5-day change	1st Jan Change
80.19 ^EUR	-0.90%		-2.89%	-3.06%

10/04	SANOFI : JP Morgan is Neutral	ZD
10/04	SANOFI : UBS reaffirms its Neutral rating	ZD

All News

10/04	SANOFI : JP Morgan is Neutral	ZD
10/04	SANOFI : UBS reaffirms its Neutral rating	ZD
09/04	Sanofi Now Holds Marketing Authorization for COVID-19 Vaccine Nuvaxovid in Canada	MT
09/04	Sanofi's Covid-19 vaccine Nuvaxovid authorised in Canada	RE
09/04	Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada	CI
08/04	Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents	GL
08/04	Novavax Shareholder Shah Capital to Vote Against Board Nominees, Executive Compensation	MT
08/04	SANOFI : Jefferies reiterates its Buy rating	ZD
08/04	Shah Capital intends to vote against Novavax's board nominees, executive compensation	RE
08/04	AlphaValue/Baader Europe Lowers Target Price, Estimates for Sanofi Amid R&D Setbacks	MT
07/04	AlphaValue turns less bullish on Sanofi
07/04	Sanofi: Treatment for re-rating isn’t easy
07/04	SANOFI : JP Morgan reiterates its Neutral rating	ZD
07/04	Sanofi Says Lunsekimig Meets Primary, Key Secondary Endpoints in Phase 2 Respiratory Studies	MT
07/04	Sanofi reports positive data in two respiratory diseases
07/04	Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP	CI
07/04	Sanofi Says Lunsekimig Meets Primary Endpoints in Respiratory Studies, Misses in Dermatitis	MT
07/04	Sanofi/Lunsekimig: exploratory velvet phase 2b study did not meet its primary endpoint	RE
07/04	Sanofi : lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP	PU
07/04	Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP	GL
03/04	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
02/04	Pharma sector facing potential tariff hikes?
01/04	Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease	AQ
01/04	European Equities Traded in the US as American Depositary Receipts Rising Sharply in Wednesday Trading	MT
01/04	Adragos Pharma GmbH backed by FSN Capital VI acquired Sterile Fill-finish facility in Maisons-Alfort, France from Sanofi.	CI